Aura Biosciences, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aura Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $80.00K, a 3900.00% increase year-over-year.
- Aura Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $56.00K.
- Aura Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.01M, a 58.99% increase year-over-year.
- Aura Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $2.00K, a 97.59% decline year-over-year.
- Aura Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $1.01M, a 28.77% decline from fiscal 2024.
- Aura Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.42M, a 3.05% increase from fiscal 2023.
- Aura Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $1.38M, a 220.00% increase from fiscal 2022.
- Aura Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $430.00K, a 23.56% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $80.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $56.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $1.01M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $1.01M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $2.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $1.42M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $634.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $83.00K 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $158.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $1.38M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $202.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $660.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $145.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $430.00K 10-K · filed 2024-03-27 | |
| 2022-09-30 | $104.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $309.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $17.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $348.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $20.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $20.00K 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $265.00K 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $163.00K 10-K · filed 2022-03-23 | |
| 2020-09-30 | $18.00K 10-Q · filed 2021-11-24 | |
| 2020-06-30 | $97.00K 10-Q · filed 2021-11-24 | |
| 2020-03-31 | $33.00K 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |